223 related articles for article (PubMed ID: 31622990)
1. Value of Dynamic Contrast-Enhanced (DCE) MR Imaging in Peripheral Lesions in PI-RADS-4 Patients.
Ullrich T; Quentin M; Arsov C; Laqua N; Abrar D; Hiester A; Albers P; Antoch G; Schimmöller L
Rofo; 2020 May; 192(5):441-447. PubMed ID: 31622990
[TBL] [Abstract][Full Text] [Related]
2. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
3. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
5. Proposed Adjustments to PI-RADS Version 2 Decision Rules: Impact on Prostate Cancer Detection.
Rosenkrantz AB; Babb JS; Taneja SS; Ream JM
Radiology; 2017 Apr; 283(1):119-129. PubMed ID: 27783538
[TBL] [Abstract][Full Text] [Related]
6. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
Ullrich T; Arsov C; Quentin M; Laqua N; Klingebiel M; Martin O; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Accuracy of MRI-Ultrasound Fusion Targeted Biopsy Based on PI-RADS v2.1 Category in Transition/Peripheral Zone of the Prostate.
Liu Y; Wang S; Xu G; Zhou B; Zhang Y; Ye B; Xiang L; Zhang Y; Xu H
J Magn Reson Imaging; 2023 Sep; 58(3):709-717. PubMed ID: 36773016
[TBL] [Abstract][Full Text] [Related]
8. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
[No Abstract] [Full Text] [Related]
9. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
10. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Dynamic Contrast-enhanced and Diffusion MRI to PI-RADS for Detecting Clinically Significant Prostate Cancer.
Tavakoli AA; Hielscher T; Badura P; Görtz M; Kuder TA; Gnirs R; Schwab C; Hohenfellner M; Schlemmer HP; Bonekamp D
Radiology; 2023 Jan; 306(1):186-199. PubMed ID: 35972360
[TBL] [Abstract][Full Text] [Related]
12. Predictors of prostate cancer detection in MRI PI-RADS 3 lesions - Reality of a tertiary center.
Araújo D; Gromicho A; Dias J; Bastos S; Maciel RM; Sabença A; Xambre L
Arch Ital Urol Androl; 2023 Dec; 95(4):11830. PubMed ID: 38117217
[TBL] [Abstract][Full Text] [Related]
13. MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
Schimmöller L; Quentin M; Arsov C; Hiester A; Buchbender C; Rabenalt R; Albers P; Antoch G; Blondin D
Eur Radiol; 2014 Oct; 24(10):2582-9. PubMed ID: 24972954
[TBL] [Abstract][Full Text] [Related]
14. Population net benefit of prostate MRI with high spatiotemporal resolution contrast-enhanced imaging: A decision curve analysis.
Prabhu V; Rosenkrantz AB; Otazo R; Sodickson DK; Kang SK
J Magn Reson Imaging; 2019 May; 49(5):1400-1408. PubMed ID: 30629317
[TBL] [Abstract][Full Text] [Related]
15. Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer.
Wang B; Gao J; Zhang Q; Zhang C; Liu G; Wei W; Huang H; Fu Y; Li D; Zhang B; Guo H
Abdom Radiol (NY); 2020 Feb; 45(2):547-555. PubMed ID: 31907568
[TBL] [Abstract][Full Text] [Related]
16. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
17. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
[TBL] [Abstract][Full Text] [Related]
18. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
19. [Effects of dynamic contrast enhancement on diffusion weighted imaging score of 3 in prostate imaging reporting and data system version 2 of peripheral zone].
Wang W; Shao ZH; Huang XH; Xu Y; Feng X; Wang PJ
Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):1002-1006. PubMed ID: 32294857
[No Abstract] [Full Text] [Related]
20. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
